GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synmosa Biopharma Corp (ROCO:4114) » Definitions » Total Long-Term Liabilities

Synmosa Biopharma (ROCO:4114) Total Long-Term Liabilities : NT$1,792 Mil (As of Sep. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Synmosa Biopharma Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Synmosa Biopharma's Total Long-Term Liabilities for the quarter that ended in Sep. 2024 was NT$1,792 Mil.

Synmosa Biopharma Total Long-Term Liabilities Historical Data

The historical data trend for Synmosa Biopharma's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synmosa Biopharma Total Long-Term Liabilities Chart

Synmosa Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,718.23 2,863.18 2,332.54 2,230.98 1,509.26

Synmosa Biopharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,432.39 1,509.26 1,402.72 1,687.88 1,791.76

Synmosa Biopharma Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Synmosa Biopharma Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Synmosa Biopharma's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Synmosa Biopharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synmosa Biopharma Corp (ROCO:4114) » Definitions » Total Long-Term Liabilities
Comparable Companies
TPE:3705 ROCO:6576 TPE:1789 ROCO:4105 TPE:1720 TPE:4119 ROCO:6620 ROCO:6785 TPE:4746 ROCO:4166 ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA NSE:DIVISLAB XSWX:SDZ VTRS
Traded in Other Exchanges
N/A
Address
No. 6, Gongye 1st Road, Hukou Township, Hsinchu County, Hsinchu, TWN
Website
https://www.synmosa.com.tw
Synmosa Biopharma Corp is engaged in the research and development, manufacturing, marketing, and distribution of pharmaceutical products, medical devices, cosmetics, animal drugs, chemical food additives, and beverages. It is also involved in manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. The company provides prescription, OTC medicines, and healthcare products under its Synmosa trademark. The reporting segments of the company are; the Generic Drugs segment which derives key revenue, and the Active Pharmaceutical Ingredients segment.

Synmosa Biopharma Headlines

No Headlines